| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
137,271,000 |
| Market
Cap: |
4.76(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,198,018 |
| 52
Week Range: |
$29.84 - $60.16 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1083 |
| Guru Rank Value : 0 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
85,827 |
272,505 |
460,958 |
926,916 |
| Total Sell Value |
$3,028,246 |
$11,199,093 |
$21,522,981 |
$47,686,051 |
| Total People Sold |
7 |
8 |
9 |
10 |
| Total Sell Transactions |
19 |
41 |
72 |
114 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wysenski Nancy |
Director |
• • – |
2025-04-15 |
4 |
A |
$38.56 |
$6,247 |
D/D |
162 |
23,277 |
|
- |
|
| Henderson John T |
Director |
• • – |
2025-04-15 |
4 |
S |
$38.66 |
$123,325 |
D/D |
(3,190) |
66,348 |
|
10% |
|
| Henderson John T |
Director |
• • – |
2025-04-15 |
4 |
OE |
$6.21 |
$124,200 |
D/D |
20,000 |
69,538 |
|
- |
|
| Harrington Robert Arthur |
Director |
• • – |
2025-04-15 |
4 |
A |
$38.56 |
$12,493 |
D/D |
324 |
14,982 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-04-15 |
4 |
A |
$38.56 |
$12,493 |
D/D |
324 |
25,961 |
|
- |
|
| Henderson John T |
Director |
• • – |
2025-04-15 |
4 |
A |
$38.56 |
$21,247 |
D/D |
551 |
66,348 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2025-04-15 |
4 |
A |
$38.56 |
$6,247 |
D/D |
162 |
24,848 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-04-10 |
4 |
S |
$36.77 |
$183,850 |
D/D |
(5,000) |
422,629 |
|
8% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-04-08 |
4 |
S |
$36.18 |
$72,360 |
D/D |
(2,000) |
140,255 |
|
-0% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-04-08 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,255 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-04-07 |
4 |
S |
$35.78 |
$103,261 |
D/D |
(2,886) |
64,689 |
|
4% |
|
| Harrington Robert Arthur |
Director |
• • – |
2025-04-03 |
4 |
S |
$39.43 |
$17,744 |
D/D |
(450) |
14,658 |
|
14% |
|
| Blum Robert I |
President & CEO |
• • – |
2025-03-31 |
4 |
S |
$40.75 |
$611,250 |
D/D |
(15,000) |
427,629 |
|
14% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-03-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
200 |
140,255 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-03-18 |
4 |
S |
$43.58 |
$87,160 |
D/D |
(2,000) |
140,455 |
|
20% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-03-18 |
4 |
OE |
$10.60 |
$21,200 |
D/D |
2,000 |
142,455 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-03-17 |
4 |
S |
$45.14 |
$943,426 |
D/D |
(20,900) |
37,663 |
|
23% |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-03-17 |
4 |
OE |
$23.26 |
$486,134 |
D/D |
20,900 |
58,563 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-03-17 |
4 |
S |
$44.38 |
$123,155 |
D/D |
(2,775) |
34,888 |
|
23% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-03-17 |
4 |
S |
$44.38 |
$194,784 |
D/D |
(4,389) |
101,005 |
|
23% |
|
| Blum Robert I |
President & CEO |
• • – |
2025-03-17 |
4 |
S |
$44.38 |
$561,318 |
D/D |
(12,648) |
326,533 |
|
23% |
|
| Blum Robert I |
President & CEO |
• • – |
2025-03-17 |
4 |
S |
$44.65 |
$1,116,250 |
D/D |
(25,000) |
339,181 |
|
23% |
|
| Lee Sung |
EVP, Chief Financial Officer |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
32,687 |
74,442 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
39,450 |
144,844 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
32,687 |
70,350 |
|
- |
|
269 Records found
|
|
Page 1 of 11 |
|
|
0.30 (0.87%) 
